REFERENCES
1 – Marsella and Benedetto. Atopic dermatitis in animals and people: an update and comparative review. Vet Sci . 2017; 4(37):1-19.
2 – Noli C. Assessing quality of Life for pets with dermatologic disease and their owners. Vet Clin North Am Small Anim Pract . 2019; 49(1):83–93.
3 – Marsella R, Girolomoni G. Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol . 2009; 129(10):2351-2357.
4 – Wilhem S, Kovalik M, Favrot C. Breed‐associated phenotypes in canine atopic dermatitis. Vet Dermatol . 2011; 22(2):143–149.
5 – Mueller RS, Jensen‐Jarolim E, Roth‐Walter F et al . Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs. Allergy . 2018; 73(10):1989–1999.
6 – Mueller RS. Update on Allergen Immunotherapy. Vet Clin North Am Small Animal Pract . 2019; 49(1):1–7.
7 – Olivry T, DeBoer DJ, Favrot C et al . Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol . 2010; 21(3):233–248.
8 – Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J . 2016; 207:29–37.
9 – DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a review. Vet Dermatol . 2017; 28(1):25-e6.
10 – Fischer NM, Mueller RS. Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update. Curr Dermatol Rep . 2019; 8(4):297–302.
11 – Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an effective and safe alternative route for canine atopic dermatitis.Schweiz Arch Tierheilkd . 2016; 158(9):646-652.
12 – Willemse A, Van den Brom WE, Rijnberk A. Effect of hyposensitisation on atopic dermatitis in dogs. J Am Vet Med Assoc . 1984; 184(10):1277–80.
13 – Park S, Ohya F, Yamashita K et al . Comparison of response to immunotherapy by intradermal skin test and antigen-specific IgE in canine atopy. J Vet Med Sci . 2000; 62(9):983–988.
14 – Zur G, White SD, Ihrke PJ et al. Canine atopic dermatitis: a retrospective study of 169 cases examined at the University of California, Davis, 1992-1998. Part II. Response to hyposensitisation.Vet Dermatol . 2002; 13(2):103–111.
15 – Schnabl B, Bettenay SV, Dow K et al . Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis.Vet Rec. 2006; 158(3):81–85.
16 – Marsella R, Ahrens K. Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study. J Allergy Ther . 2013; 04(06).
17 – Timm K, Mueller RS, Nett‐Mettler CS. Long‐term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.Vet Dermatol . 2018; 29(2):123-e49.
18 – Fischer NM, Rostaher A, Favrot C. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long‐term control of dogs with nonseasonal atopic dermatitis. Vet Dermatol . 2020; 31(5):365-e96.
19 – Olivry T, DeBoer DJ, Favrot C et al . Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). Bmc Vet Res . 2015; 11(1):210.
20 – Johansen P, Moos S von, Mohanan D et al . New routes for allergen immunotherapy. Hum Vacc Immunother . 2012; 8(10):1525–1533.
21 – Senti G, Kundig TM. Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and Intradermal.Immunol Allergy Clin North Am . 2016; 36(1):25–37.
22 – Ramió-Lluch L, Brazís P, Ferrer L et al . Allergen-specific immunotherapy in dogs with atopic dermatitis: is owner compliance the main success-limiting factor? Vet Rec . 2020; 187(12):493–493.
23 – James C, Bernstein DI. Allergen immunotherapy. Curr Opin Allergy Cl . 2017; 17(1):55–59.
24 – Senna G, Caminati M, Lockey RF. Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? Curr Treat Options Allergy . 2015; 2(1):39–53.
25 – Canonica GW, Cox L, Pawankar R et al . Sublingual immunotherapy: World Allergy Organization position paper 2013 update.World Allergy Organization J . 2014; 7(1):1–52.
26 – DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol . 2016; 27(2):82-e24.
27 – Glenn GM, Taylor DN, Li X et al . Transcutaneous immunisation: A human vaccine delivery strategy using a patch. Nat Med . 2000; 6(12):1403–1406.
28 – Dell K, Koesters R, Gissmann L. Transcutaneous immunisation in mice: Induction of T‐helper and cytotoxic T lymphocyte responses and protection against human papillomavirus–induced tumors. Int J Cancer . 2006; 118(2):364–372.
29 – Frech SA, DuPont HL, Bourgeois AL et al . Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet . 2008; 371(9629):2019–2025.
30 – Kozaka S, Tahara Y, Wakabayashi R et al . Transcutaneous Cancer Vaccine Using a Reverse Micellar Antigen Carrier. Mol Pharmaceut . 2020; 17(2):645–655.
31 – Senti G, Graf N, Haug S et al . Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.J Allergy Clin Immun . 2009; 124(5):997–1002.
32 – Senti G, Moos S, Tay F et al . Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy . 2015; 70(6):707–710.
33 – Dioszeghy V, Mondoulet L, Laoubi L et al . Antigen Uptake by Langerhans Cells Is Required for the Induction of Regulatory T Cells and the Acquisition of Tolerance During Epicutaneous Immunotherapy in Ova-Sensitised Mice. Front Immunol . 2018; 9:1951.
34 – Hasegawa H, Matsumoto T. Mechanisms of Tolerance Induction by Dendritic Cells In Vivo. Front Immunol . 2018; 9:350.
35 – Senti G, Moos S, Tay F et al . Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immun . 2012; 129(1):128–135.
36 – Jones SM, Sicherer SH, Burks AW et al . Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immun . 2017; 139(4):1242-1252.
37 – Sampson HA, Shreffler WG, Yang WH et al . Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomised Clinical Trial. Jama . 2017; 318(18):1798–1809.
38 – Fleischer DM, Shreffler WG, Campbell DE et al . Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.J Allergy Clin Immun . 2020; 146(4):863–874.
39 – Wavrin S, Mondoulet L, Dioszeghy V et al. Allergen Capture by DCs during epicutaneous immunotherapy is Enhanced by Modulating the Dose and the Surface Area of the Patch. J Allergy Clin Immunol . 2017; 139(2):AB257.
40 – D’souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Del . 2016; 13(9):1–19.
41 – Shimada K, Yoshihara T, Yamamoto et al . Transepidermal Water Loss (TEWL) Reflects Skin Barrier Function of Dog. J Vet Med Sci . 2008; 70(8):841–843.
42 – Hill PB, Lau P, Rybnicek J. Development of an owner‐assessed scale to measure the severity of pruritus in dogs. Vet Dermatol . 2007; 18(5):301–308.
43 – Rybníček J, Lau‐Gillard PJ, Harvey R et al . Further validation of a pruritus severity scale for use in dogs. Vet Dermatol . 2009; 20(2):115–122.
44 – High EJ, Olivry T. Development and validation of a graphic 2D investigator’s global assessment instrument for grading the overall severity of atopic dermatitis in dogs. Vet Dermatol . 2020; 31(3):207-e43.
45 – Olivry T, Bensignor E, Favrot C et al . Development of a core outcome set for therapeutic clinical trials enrolling dogs with atopic dermatitis (COSCAD’18). Bmc Vet Res . 2018; 14(1):238.
46 – Noli C, Minafò G, Galzerano M. Quality of life of dogs with skin diseases and their owners. Part 1: development and validation of a questionnaire. Vet Dermatol . 2011; 22(4):335–343.
47 – Pinto M, Marto J, Ramió-Lluch L et al . Epicutaneous immunotherapy as a novel route of allergen administration in dogs with atopic dermatitis: a proof-of-concept study – 32nd European Veterinary Dermatology Congress (online) 16-16 September 2021 Abstracts. Vet Dermatol . 2021;32: 419-433 (Abstract).
48 – Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol . 2006; 6(10):761–771.
49 – Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immun . 2009; 124(2):292-300.e97.
50 – Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immun . 2017; 140(6):1485–1498.
51 – Keppel KE, Campbell KL, Zuckermann FA, et al. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy.Vet Immunol Immunop . 2008; 123(3–4):337–344.